Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens

Abstract The attenuated poxvirus vectors MVA and NYVAC are now in clinical trials against HIV/AIDS. Due to the vectors restricted replication capacity in human cells, approaches to enhance their immunogenicity are highly desirable. Here, we have analyzed the ability of a soluble form of hexameric CD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2009-05, Vol.27 (24), p.3165-3174
Hauptverfasser:	Gómez, Carmen E, Nájera, José L, Sánchez, Raquel, Jiménez, Victoria, Esteban, Mariano
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - pharmacology AIDS Vaccines - immunology Allergy and Immunology Animals Antigens Applied microbiology Biological and medical sciences CD40 Ligand - pharmacology CD8-Positive T-Lymphocytes - immunology Deoxyribonucleic acid DNA Drug resistance Female Fundamental and applied biological sciences. Psychology Genetic Vectors HIV HIV Antigens - genetics HIV Antigens - immunology HIV-1 - immunology Human immunodeficiency virus 1 Immune response Immune system Immunization, Secondary Immunogenicity Medical research MegaCD40L Mice Mice, Inbred BALB C Microbiology Miscellaneous Mouse model MVA-B NYVAC-B Poxviridae - genetics Poxvirus Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, DNA - immunology Vaccines, Synthetic - immunology Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!